Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | IL1RN | P18510 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | KMT5B | Q4FZB7 | 1/20 | 0.30 |
| ▸ | KMT5C | Q86Y97 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424574 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL18807211 | 0.78 | HTR2C (0.39) | HTR2AHTR2CHTR2BADRA1AFNTA | |
| SCHEMBL379328 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL30666992 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL29532721 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL12583743 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL16420396 | 0.78 | HTR2C (0.39) | HTR2AHTR2CHTR2BADRA1AFNTA | |
| SCHEMBL15267245 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BFNTAFNTB | |
| SCHEMBL20510062 | 0.78 | IL1RN (0.46) | HTR2AHTR2CHTR2BIL1RNERAP2 | |
| SCHEMBL25667811 | 0.78 | HTR2A (0.39) | HTR2AHTR2CHTR2BIL1RNERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | MERCK SHARP & DOHME CORP. (US) | 2019-11-12 | — | — | US | disclosed |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2018-11-15 | — | — | US | disclosed |
| EP-3220910-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | Merck Sharp & Dohme Corp. (US) | 2017-09-27 | — | — | EP | disclosed |
| WO-2016081290-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME CORP. (US) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472347-B2 | Aminopyrazine compounds with A2A antagonist properties | ADORA2A, ADORA1, ADORA3 | HTR2A 6/4885HTR2C 15/4885HTR2B 39/4885 |
| US-20180327385-A1 | AMINOPYRAZINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | ADORA2A, ADORA1, ADORA3 | HTR2A 6/4885HTR2C 15/4885HTR2B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.